Skip Navigation

Eric Lee Nuermberger, M.D.

Headshot of Eric Lee Nuermberger
  • Professor of Medicine


Infectious Disease, Infectious Diseases, Tuberculosis more

Research Interests

Drug development for tuberculosis and non-tuberculous mycobacterial infections, including Mycobacterium ulcerans disease (Buruli ulcer) more

Request an Appointment

Insurance Information

Main Phone


Outside of Maryland

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-1725
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287 map

Johns Hopkins Bayview Medical Center

Appointment Phone: 410-550-0501
4940 Eastern Avenue
Baltimore, MD 21224 map


Dr. Eric Nuermberger is a Professor of Medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include infectious disease and tuberculosis. 

Dr. Nuermberger received his undergraduate degree in psychology from Kenyon University. He earned his M.D. from Vanderbilt. He completed his residency and a fellowship in infectious diseases at Johns Hopkins. 

His research interest includes the experimental chemotherapy of TB and non-tuberculous mycobacterial infections. He works with mice and other models to develop new, shorter drug regimens.

Dr. Nuermberger is a member of several professional organizations, including the American Society for Microbiology, the Infectious Diseases Society of America, and the American Thoracic Society. more


  • Professor of Medicine

Departments / Divisions



  • MD; Vanderbilt University School of Medicine (1996)


  • Internal Medicine; Johns Hopkins University School of Medicine (1999)


  • Infectious Diseases; Johns Hopkins University School of Medicine (2000)
  • Infectious Diseases; Johns Hopkins University School of Medicine (2003)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (2002)

Research & Publications

Research Summary

Dr. Nuermberger’s primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new drugs and drug regimens. A major goal is to identify new agents that can be combined together in novel regimens or combined with existing drugs to shorten the duration of TB therapy.

A newer interest is to develop improved animal models of non-tuberculous mycobacterial infection to enable a similar approach to drug and regimen development for these difficult-to-treat infections.

He is also working with an innovative flow-controlled in vitro pharmacodynamic system to gain a better understanding of the pharmacodynamics of drug efficacy and selection of drug-resistant mutants during exposure to currently used agents.

Technology Expertise Keywords

Tuberculosis; Drug Development; Antibiotic Resistance; Pharmacodynamics; Infectious Disease; Infectious Diseases

Selected Publications

View all on PubMed

Peer-reviewed original research publications

  1. Nuermberger E, Choi M, Scheel PJ, Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58:1253-60.
  2. Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother. 2002;46:1875-9.
  3. Nuermberger E, Yoshimatsu T, Tyagi S, O’Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-6. 4. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Paucibacillary tuberculosis in mice after prior aerosol immunization with BCG. Infect Immun. 2004;72:1065-71.
  4. Nuermberger EL,Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170:1131-4.
  5. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL,Grosset J, Bishai WR. Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis within Artificial Granulomas in Mice. J Exp Med. 2004;200:647-57.
  6. Nuermberger E, Bartlett JG. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100-7.
  7. Nuermberger E, Juan G, Hardick J, Bartlett JG, Auwaerter PG, Rothman RE. Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol. 2005;43:3221-6.
  8. Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Bactericidal activity of the nitroimidazopyran, PA-824, in the murine model of tuberculosis. Antimicrob Agents Chemother. 2005; 49:2289-93.
  9. Nuermberger EL. Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in Murine Tuberculosis. Am J Respir Crit Care Med. 2005;172:1457-62.
  10. Nuermberger E, Tyagi S, Williams K, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med. 2005;172:1452-6.
  11. Nuermberger E, Helke K, Bishai WR. The Low-dose Aerosol Model of Pneumococcal Pneumonia in the Mouse: Utility for Evaluation of Antimicrobial Efficacy. Int J Antimicrob Agents 2005;26:497-503.
  12. Nuermberger EL. Potent Twice-weekly Rifapentine-containing Regimens in Murine Tuberculosis. Am J Respir Crit Care Med. 2006; 2006;74:94-101.
  13. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in the murine model of tuberculosis. Antimicrob Agents Chemother. 2006;50:2621-5.
  14. Nuermberger E, Grosset J, McMurray DN, Karakousis PC, Lamichhane G, Bishai WR. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs compared with mice. J Infect Dis. 2007;195:1634-42.
  15. Nuermberger E, Grosset J. Promising clinical efficacy of the combination streptomycin - rifampin for the treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51:4029-35.
  16. Nuermberger E, Zhang Y. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol. 2007;56:1047-51.
  17. Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Medicine, 2007;4:e344.
  18. Nuermberger E, Tyagi S, Bishai WR, Grosset J. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother. 2007;51:4261-6.
  19. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in the murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52:1522-4.
  20. Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in the murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52:3664-8.
  21. Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med. 2008;178:989-93.
  22. Nuermberger E, Chaisson RE, Dorman SE. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008;52:4037-42.
  23. Nuermberger E. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother. 2009;53:1314-9.
  24. Nuermberger EL, Bishai WR. Role of the dosR/dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun. 2009;77:1230-7.
  25. Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.Am J Respir Crit Care Med. 2009;180:273-80.
  26. Nuermberger EL. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009;180:371-6.
  27. Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis. Antimicrob Agents Chemother. 2009;53:4178-84.
  28. Nuermberger EL, Grosset JH, Karakousis PC. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis. 2009;200:1136-43.
  29. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2009;180:1151-7.
  30. Nuermberger EL, Um P, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Non-invasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother. 2009;53:4879-84.
  31. Nuermberger EL. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother. 2010;54:2806-13.
  32. Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR. The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models. PLoS One. 2010;5:e10289.
  33. Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011; 55:239-45.
  34. Nuermberger EL. Using bioluminescence to monitor treatment response in real-time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother. 2011; 55:56-61.
  35. Nuermberger EL, Grosset J. Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Neglected Trop Dis. 2011; 5:e933.
  36. Nuermberger EL. Activity of the fluoroquinolone DC-159a in the initial and continuation phase treatment of murine tuberculosis. Antimicrob Agents Chemother. 2011; 55:1781-3.
  37. Nuermberger EL, Grosset JH. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med. 2011; 183:1254-61.
  38. Nuermberger EL, Grosset J. BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Neglected Trop Dis. 2011; 5:e985.
  39. Nuermberger EL, Grosset JH, Karakousis PC. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother 2011; 66:1560-6.
  40. Zhang T, Li S, Williams K, Andries K, Nuermberger E. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2011; 184:732-7.
  41. Mdluli KE, Nuermberger EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agent Chemother 2011; 55:5485-92.
  42. Nuermberger EL, Jain SK. Mouse model of necrotic TB granulomas develops hypoxic lesions. J Infect Dis 2012; 205:595-602.
  43. Nuermberger EL. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One 2012; 7:e29774.
  44. Nuermberger EL, Hubbard WC, Fuchs EJ, Melia M, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of rifapentine, an anti-tuberculosis drug, in healthy volunteers. Clin Pharmacol Ther 2012; 91:881-8.
  45. Nuermberger EL. Sterilizing activity of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agent Chemother 2012; 56:3114-20.
  46. Nuermberger EL, Grosset JH, Karakousis PC. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agent Chemother 2012; 56:3726-31.
  47. Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agent Chemother 2012; 56:4331-40.
  48. Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium. J Infect Dis 2012; 206:1030-40.
  49. Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosisTuberculosis 2012; 92:453-88.
  50. Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci USA 2012; 109:16004-11.
  51. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother. 2010;65:729-34.
  52. Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother. 2010;65:2172-5.
  53. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother. 2011;55:1527-32.
  54. Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR Jr, Grosset JH. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian J Med Res. 2012;136:808-14.
  55. Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, Grosset JH. Bactericidal activity does not predict sterilizing activity: The case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis. 2013;7:e2085.

Review articles

  1. Nuermberger E. Current concepts in HIV-associated nephropathy. The Hopkins HIV Report 1999;11:12-4.
  2. Nuermberger EL and Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: It’s all relative. Clin Infect Dis. 2004;38:99-103.
  3. Nuermberger E and Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis. 2004;23:243-55.
  4. Nuermberger E, Bishai WR, Grosset JH. Latent tuberculosis infection. Semin Respir Crit Care Med. 2004;25:317-36.
  5. Nuermberger E and Bishai WR. Antibiotic Resistance in Streptococcus pneumoniae: What Does the Future Hold? Clin Infect Dis. 2004;38 Suppl 4:S363-71.
  6. Nuermberger E. Current Issues in the Diagnosis, Evaluation, and Management of Gastrointestinal Infections. Advanced Studies in Medicine 2005;5:297-304.
  7. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005;5:275-86.
  8. Nuermberger E. Murine Models of Pneumococcal Pneumonia and their Applicability to the Study of Tissue-Directed Antimicrobials. Pharmacotherapy 2005;25:134S-139S.
  9. Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis 2008;88 Suppl1:S65-74.
  10. Nuermberger E. Use of animal models in the development of new drugs for tuberculosis. Semin Respir Crit Care Med. 2008;29:542-51.
  11. Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010;15:764-78.
  12. Burman W, Dooley KE, Nuermberger E. The rifamycins: Renewed interest in an old drug class. Prog Respir Research 2011; 40:25-31.
  13. Nuermberger E. The role of the mouse model in the evaluation of new anti-tuberculosis drugs. Prog Respir Research 2011; 40:145-52.
  14. Nuermberger EL, Almeida DV, Grosset JH. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol 2011; 6:1185-98.
  15. Nuermberger EL. 2011: The year in review. Part I: Tuberculosis. Int J Tuberc Lung Dis 2012; 740-8.
  16. Nuermberger EL. World Health Organization Group 5 drugs for the treatment of drug-resistant tuberculosis: Unclear efficacy or untapped potential? J Infect Dis 2012; in press.
  17. Nuermberger E. Old drugs, new purpose: Retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis 2012; 55:572-81.
  18. Nuermberger EL. Tuberculosis in transplant recipients: diagnostic and therapeutic dilemmas. Transplant Infect Dis. 2008;10:229-30.
  19. Nuermberger E and Mitchison D. Once-weekly treatment of tuberculosis with the diarylquinoline R207910 - a real possibility. Am J Respir Crit Care Med. 2009;179:2-3.
  20. Nuermberger EL. Confronting multidrug-resistant tuberculosis. N Engl J Med 2012; 366:2223-4.

Case Reports

  1. Nuermberger E. Cases from the Osler Medical Service at Johns Hopkins University. Am J Med. 2002;112:70-1.
  2. Nuermberger E. Cases from the Osler Medical Service at Johns Hopkins University. Am J Med. 2002;112:494-5.
  3. Nuermberger EL, Ness PM. Polymerized human hemoglobin use in acute chest syndrome: a case report. Transfusion 2002;42:1422-7.
  4. Nuermberger EL and Bishai WR. Significance of macrolide resistance in Streptococcus pneumoniaeJ Antimicrob Chemother. 2003;52:524-5. 
  5. Francis JS, Carroll K, Nuermberger E, Bartlett JG. Reply to Wargo and Eiland. Clin Infect Dis. 2005;40:1378-9.
  6. Nuermberger EL, Grosset JH. Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agent Chemother. 2007;51:403-4.
  7. Nuermberger E. Reply to Seddon, Schaaf, and Hesseling. Clin Infect Dis 2013; 56:168-9.
  8. Nuermberger E & Bishai W. Management of community-acquired pneumonia caused by drug-resistant Streptococcus pneumoniae. In: Management of Infections with Multiple Drug Resistant Organisms, S.H. Gillespie (Ed.), Humana Press: Totowa, NJ, 2004, pp 3-30.
  9. Nuermberger E. Urinary Tract Infections. In: The Osler Medical Handbook, A. Cheng & A. Zaas (Eds.), Mosby: Philadelphia, 2003, pp 735-43.
  10. Nuermberger E & Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. In: Antimicrobial Therapy and Vaccines II, 2nd edition, V.L. Yu et al. (Eds.), Apple Trees Productions: New York, 2005, pp 391-404.
  11. Nuermberger E. Urinary Tract Infections. In: The Osler Medical Handbook, 2nd edition, K.R. Nilsson & J.P. Piccini (Eds.), Saunders: Philadelphia, 2006, pp 663-71.
  12. Nuermberger E. Tuberculosis. In: The Osler Medical Handbook, 2nd edition, K.R. Nilsson & J.P. Piccini (Eds.), Saunders: Philadelphia, 2006, pp 640-7.
  13. Nuermberger E. Acute Gastroenteritis and Associated Conditions. In: Principles of Ambulatory Medicine, 7th edition, N.H. Fiebach et al (Eds.), Lippincott Williams & Wilkins: Philadelphia, 2007, pp 513-27.
  14. Nuermberger EL, Peloquin CA, Grosset JH. Pharmacological Issues in the Development of New Antituberculosis Drugs. In: Development of New Antituberculosis Drugs, W.W. Yew (Ed.), Nova Science Publishers: New York, 2007, pp 53-73.
  15. Nuermberger EL. New developments in treatment. In: Clinical Tuberculosis, 4th edition, P.D.O. Davies et al (Eds.), Chapman & Hall: London, 2008, pp 243-52.
  16. Nuermberger E. Pneumococcal endocarditis and the Austrian syndrome: The clinical utility of medical eponyms. Osler Medical Journal 1999;Volume 5, February, 1999. 

Current Author on sections/modules listed below:

  1. Acute osteomyelitis, Chronic osteomyelitis, Acute septic arthritis, Lyme arthritis,
  2. Prosthetic Joint Infection, Diabetic Foot Infection, Spinal Epidural Abscess

Former Author on sections:

  1. Antibiotic profiles, Bug/drug tables, Adverse effects

Current Author on sections/modules listed below:

  1. Bacterial Pneumonia, Streptococcus pneumoniae, Rhodococcus equi,
  2. HIV-Associated Nephropathy

Academic Affiliations & Courses

Graduate Program Affiliation

Activities & Honors


  • Highlighted Abstract, American Thoracic Society Annual Meeting, 2007
  • Highlighted Abstract, American Thoracic Society Annual Meeting, 2006
  • Clinical Infectious Diseases Award for Outstanding Review, 2005


  • American Society for Microbiology
  • American Thoracic Society
  • Infectious Diseases Society of America
  • International Union of Tuberculosis and Lung Disease

Professional Activities

  • Microbiology, Tuberculosis, and Pulmonary Infections Program Committee, American Thoracic Society, 2004
  • Representative, Stop TB Partnership Working Group on New Drugs, American Thoracic Society, 2006
  • Board of Directors Nominating Committee, Global Alliance Stakeholders Association, 2007
Is this you? Edit Profile
back to top button